Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia : implications for the biology, management, and therapy of the diseaseVALENT, Peter.British journal of haematology. 2008, Vol 142, Num 3, pp 361-378, issn 0007-1048, 18 p.Article

Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?VALENT, Peter.European journal of clinical investigation. 2010, Vol 40, Num 10, pp 918-931, issn 0014-2972, 14 p.Article

Pathogenesis, classification, and therapy of eosinophilia and eosinophil disordersVALENT, Peter.Blood reviews. 2009, Vol 23, Num 4, pp 157-165, issn 0268-960X, 9 p.Article

Targeted genes in haematology: the PI3-kinase-Akt-mTOR pathway of signalling in leukaemic cellsVALENT, Peter.European journal of clinical investigation. Supplement. 2004, Vol 34, Num 2, issn 0960-135X, 54 p.Serial Issue

Mast cells, thrombosis, and fibrinolysis. The emerging conceptBANKL, Hans C; VALENT, Peter.Thrombosis research. 2002, Vol 105, Num 4, pp 359-365, issn 0049-3848Article

Role of interleukins in the regulation of basophil development and secretionVALENT, Peter; DAHINDEN, Clemens A.Current opinion in hematology. 2010, Vol 17, Num 1, pp 60-66, issn 1065-6251, 7 p.Article

Histopathological and immunohistochemical aspects of mastocytosisHORNY, Hans-Peter; VALENT, Peter.International archives of allergy and immunology. 2002, Vol 127, Num 2, pp 115-117, issn 1018-2438Article

Diaenostic evaluation and classification of mastocytosisVALENT, Peter.Immunology and allergy clinics of North America. 2006, Vol 26, Num 3, issn 0889-8561, vii, 515-534 [21 p.]Article

Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findingsHORNY, Hans-Peter; VALENT, Peter.Leukemia research. 2001, Vol 25, Num 7, pp 543-551, issn 0145-2126Conference Paper

The biological and clinical significance of MLL abnormalities in haematological malignanciesMITTERBAUE-HOHENDANNER, G; MANNHALTER, C.European journal of clinical investigation. Supplement. 2004, Vol 34, Num 2, pp 12-24, issn 0960-135X, 13 p.Article

Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosisSPERR, Wolfgang R; HORNY, Hans-Peter; VALENT, Peter et al.International archives of allergy and immunology. 2002, Vol 127, Num 2, pp 140-142, issn 1018-2438Article

Mast Cell Proliferative Disorders: Current Concepts (A Report of the Year 2000 Working Conference on Mastocytosis), Vienna, Austria, 1-3 September 2000VALENT, Peter; BENNETT, John M.Leukemia research. 2001, Vol 25, Num 7, issn 0145-2126, 131 p.Conference Proceedings

How I treat patients with advanced systemic mastocytosisVALENT, Peter; SPERR, Wolfgang R; AKIN, Cem et al.Blood. 2010, Vol 116, Num 26, pp 5812-5817, issn 0006-4971, 6 p.Article

Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemiaGAIGER, A; HEINTEL, D; JÄGER, U et al.European journal of clinical investigation. Supplement. 2004, Vol 34, Num 2, pp 25-30, issn 0960-135X, 6 p.Article

The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosisBÜHRING, Hans-Jörg; STREBLE, Anna; VALENT, Peter et al.International archives of allergy and immunology. 2004, Vol 133, Num 4, pp 317-329, issn 1018-2438, 13 p.Article

Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21STREUBEL, Berthold; VALENT, Peter; LECHNER, Klaus et al.Cancer genetics and cytogenetics. 2001, Vol 124, Num 1, pp 42-46, issn 0165-4608Article

Mast cell activation syndrome: Proposed diagnostic criteriaAKIN, Cem; VALENT, Peter; METCALFE, Dean D et al.Journal of allergy and clinical immunology. 2010, Vol 126, Num 6, pp 1099-1104, issn 0091-6749, 6 p.Article

Clinical and Laboratory Parameters of Mast Cell Activation as Basis for the Formulation of Diagnostic CriteriaVALENT, Peter; HORNY, Hans-Peter; TRIGGIANI, Massimo et al.International archives of allergy and immunology. 2011, Vol 156, Num 2, pp 119-127, issn 1018-2438, 9 p.Article

Classification of cutaneous mastocytosis: a modified consensus proposal. Authors' replyHARTMANN, Karin; HENZ, Beate M; VALENT, Peter et al.Leukemia research. 2002, Vol 26, Num 5, pp 483-486, issn 0145-2126Article

Glucocorticosteroids Rescue Basophils from Dasatinib-Augmented Immunoglobulin E-Mediated Histamine ReleaseHERRMANN, Harald; BLATT, Katharina; GHANIM, Viviane et al.International archives of allergy and immunology. 2012, Vol 159, Num 1, pp 15-22, issn 1018-2438, 8 p.Article

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemiaWARSCH, Wolfgang; KOLLMANN, Karoline; HERRMANN, Harald et al.Blood. 2011, Vol 117, Num 12, pp 3409-3420, issn 0006-4971, 12 p.Article

NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cellsHUBMANN, Rainer; DÜCHLER, Markus; SCHWARZMEIER, Josef D et al.British journal of haematology. 2010, Vol 148, Num 6, pp 868-878, issn 0007-1048, 11 p.Article

Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma : a rare form of concomitant lymphoproliferative diseaseHAUSWIRTH, Alexander W; FÖDINGER, Manuela; FRITZ, Marika et al.Human pathology. 2008, Vol 39, Num 6, pp 917-924, issn 0046-8177, 8 p.Article

Leukemic challenge unmasks a requirement for PI3Kδ in NK cell-mediated tumor surveillanceZEBEDIN, Eva; SIMMA, Olivia; PICKL, Winfried F et al.Blood. 2008, Vol 112, Num 12, pp 4655-4664, issn 0006-4971, 10 p.Article

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KITGLEIXNER, Karoline V; MAYERHOFER, Matthias; PICKL, Winfried F et al.Haematologica (Roma). 2007, Vol 92, Num 11, pp 1451-1459, issn 0390-6078, 9 p.Article